Literature DB >> 30525898

Pharmacological Effects and Mechanisms of Chinese Medicines Modulating NLRP3 Inflammasomes in Ischemic Cardio/Cerebral Vascular Disease.

Yueying Li1,2, Yuntao Liu1,3, Xia Yan1,3, Qing Liu1,3,4, Yong-Hua Zhao2, Da-Wei Wang1,3.   

Abstract

Cardio/cerebral-vascular diseases seriously threaten human health and are the leading cause of death. As such, there is great interest in identifying a potential mechanism that controls the development process of cardio/cerebral vascular diseases. Present studies demonstrate that inflammasomes play an important role in the process of ischemic cardio/cerebral vascular diseases (ICCVDs). Among the pathological process of ICCVDs, inflammasomes activated the sterile inflammatory response that accelerated the development of diseases and aggravated the acute lesion of tissue. As the most thoroughly studied inflammasome, the NLRP3 inflammasome has been proven to be a potential therapeutic target for ICCVDs. In this review, we summarized the mechanisms of Chinese herbal medicine which can affect ICCVDs via the regulation of the NLRP3 inflammasome. Our study discovers that active compounds of Chinese medicines have a negative effect on NLRP3 in different ICCVDs models. Astragaloside IV may influence the receptor of the cell membrane to inhibit NLRP3 activation. Resveratrol, colchicinesis, salvianolic acid B, chrysophanol and sulforaphane may directly damage the formation of NLRP3 by inhibiting ASC or Caspase-1. Most of the active natural compounds can negatively regulate the downstream products of NLRP3 inflammasome such as IL-18 and IL1 β . In addition, Chinese medicines such as sinomenine, ruscogenin, resveratrol, arctigenin and cepharanthineas may downregulate NLRP3 inflammasome by inducing autophagy activation. Due to the advantages of multi-target effects, Chinese herbal medicine can be treated as a splendid therapy for ICCVDs by inhibiting NLRP3 inflammasome.

Entities:  

Keywords:  Cardiovascular Diseases; Cerebrovascular Diseases; Chinese Medicine; NLRP3 Inflammasome; Review

Mesh:

Substances:

Year:  2018        PMID: 30525898     DOI: 10.1142/S0192415X18500878

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  6 in total

1.  A Network Pharmacology Technique to Investigate the Synergistic Mechanisms of Salvia miltiorrhiza and Radix puerariae in Treatment of Cardio-Cerebral Vascular Diseases.

Authors:  Yang Ma; Wenjun Wang; Jiani Yang; Sha Zhang; Zhe Li; Fei Li; Shaojie Huang; Lu Lei; Kai Wang; Aidong Wen; Yi Ding
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-05       Impact factor: 2.629

Review 2.  Reversal of Epithelial-Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids.

Authors:  Chang Hoon Lee
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

3.  Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through NLRP3 Inflammasome-Mediated Pyroptosis Inhibition via Activating Nrf2.

Authors:  Lan Xiao; Ziwei Dai; Wenjing Tang; Canwen Liu; Biao Tang
Journal:  Oxid Med Cell Longev       Date:  2021-12-30       Impact factor: 6.543

Review 4.  Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases.

Authors:  Xiaopeng Ai; Peiling Yu; Lixia Peng; Liuling Luo; Jia Liu; Shengqian Li; Xianrong Lai; Fei Luan; Xianli Meng
Journal:  Front Pharmacol       Date:  2021-11-03       Impact factor: 5.810

5.  NLRP-3 Inflammasome: A Key Target, but Mostly Overlooked following SARS-CoV-2 Infection.

Authors:  Consolato M Sergi
Journal:  Vaccines (Basel)       Date:  2022-08-12

6.  Exploring the mechanism of Danggui Buxue Decoction in regulating atherosclerotic disease network based on integrated pharmacological methods.

Authors:  Hao Xu; Tianqing Zhang; Ling He; Mengxia Yuan; Xiao Yuan; Shanshan Wang
Journal:  Biosci Rep       Date:  2021-10-29       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.